🚀 VC round data is live in beta, check it out!
Eris Lifesciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for Eris Lifesciences and similar public comparables like Nektar Therapeutics, Aurinia Pharmaceuticals, Cheezheng Tibetan Medicine, Harrow and more.
Eris Lifesciences Overview
About Eris Lifesciences
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
Founded
2007
HQ
Employees
3.6K
Website
Sectors
Financials (LTM)
EV
$2B
Eris Lifesciences Financials
Eris Lifesciences reported last 12-month revenue of $346M and EBITDA of $123M.
In the same LTM period, Eris Lifesciences generated $258M in gross profit, $123M in EBITDA, and $53M in net income.
Revenue (LTM)
Eris Lifesciences P&L
In the most recent fiscal year, Eris Lifesciences reported revenue of $339M and EBITDA of $119M.
Eris Lifesciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $346M | XXX | $339M | XXX | XXX | XXX |
| Gross Profit | $258M | XXX | $230M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 68% | XXX | XXX | XXX |
| EBITDA | $123M | XXX | $119M | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 35% | XXX | XXX | XXX |
| EBIT Margin | 27% | XXX | 25% | XXX | XXX | XXX |
| Net Profit | $53M | XXX | $43M | XXX | XXX | XXX |
| Net Margin | 15% | XXX | 13% | XXX | XXX | XXX |
| Net Debt | — | — | $238M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Eris Lifesciences Stock Performance
Eris Lifesciences has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Eris Lifesciences' stock price is $14.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | -0.9% | XXX | XXX | XXX | $0.31 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEris Lifesciences Valuation Multiples
Eris Lifesciences trades at 6.5x EV/Revenue multiple, and 18.1x EV/EBITDA.
EV / Revenue (LTM)
Eris Lifesciences Financial Valuation Multiples
As of March 21, 2026, Eris Lifesciences has market cap of $2B and EV of $2B.
Equity research analysts estimate Eris Lifesciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Eris Lifesciences has a P/E ratio of 37.3x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 6.5x | XXX | 6.6x | XXX | XXX | XXX |
| EV/EBITDA | 18.1x | XXX | 18.8x | XXX | XXX | XXX |
| EV/EBIT | 24.2x | XXX | 27.0x | XXX | XXX | XXX |
| EV/Gross Profit | 8.7x | XXX | 9.7x | XXX | XXX | XXX |
| P/E | 37.3x | XXX | 46.5x | XXX | XXX | XXX |
| EV/FCF | 40.1x | XXX | 22.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Eris Lifesciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Eris Lifesciences Margins & Growth Rates
Eris Lifesciences' revenue in the last 12 month grew by 16%.
Eris Lifesciences' revenue per employee in the last FY averaged $0.1M.
Eris Lifesciences' rule of 40 is 52% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Eris Lifesciences' rule of X is 76% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Eris Lifesciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | 36% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 52% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 76% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 8% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 0% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Eris Lifesciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Nektar Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aurinia Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Cheezheng Tibetan Medicine | XXX | XXX | XXX | XXX | XXX | XXX |
| Harrow | XXX | XXX | XXX | XXX | XXX | XXX |
| Phibro Animal Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Eris Lifesciences M&A Activity
Eris Lifesciences acquired XXX companies to date.
Last acquisition by Eris Lifesciences was on XXXXXXXX, XXXXX. Eris Lifesciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Eris Lifesciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEris Lifesciences Investment Activity
Eris Lifesciences invested in XXX companies to date.
Eris Lifesciences made its latest investment on XXXXXXXX, XXXXX. Eris Lifesciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Eris Lifesciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Eris Lifesciences
| When was Eris Lifesciences founded? | Eris Lifesciences was founded in 2007. |
| Where is Eris Lifesciences headquartered? | Eris Lifesciences is headquartered in India. |
| How many employees does Eris Lifesciences have? | As of today, Eris Lifesciences has over 3K employees. |
| Is Eris Lifesciences publicly listed? | Yes, Eris Lifesciences is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Eris Lifesciences? | Eris Lifesciences trades under ERIS ticker. |
| When did Eris Lifesciences go public? | Eris Lifesciences went public in 2017. |
| Who are competitors of Eris Lifesciences? | Eris Lifesciences main competitors are Nektar Therapeutics, Aurinia Pharmaceuticals, Cheezheng Tibetan Medicine, Harrow. |
| What is the current market cap of Eris Lifesciences? | Eris Lifesciences' current market cap is $2B. |
| What is the current revenue of Eris Lifesciences? | Eris Lifesciences' last 12 months revenue is $346M. |
| What is the current revenue growth of Eris Lifesciences? | Eris Lifesciences revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Eris Lifesciences? | Current revenue multiple of Eris Lifesciences is 6.5x. |
| Is Eris Lifesciences profitable? | Yes, Eris Lifesciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Eris Lifesciences? | Eris Lifesciences' last 12 months EBITDA is $123M. |
| What is Eris Lifesciences' EBITDA margin? | Eris Lifesciences' last 12 months EBITDA margin is 36%. |
| What is the current EV/EBITDA multiple of Eris Lifesciences? | Current EBITDA multiple of Eris Lifesciences is 18.1x. |
| What is the current FCF of Eris Lifesciences? | Eris Lifesciences' last 12 months FCF is $56M. |
| What is Eris Lifesciences' FCF margin? | Eris Lifesciences' last 12 months FCF margin is 16%. |
| What is the current EV/FCF multiple of Eris Lifesciences? | Current FCF multiple of Eris Lifesciences is 40.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.